Advertisement

International Journal of Hematology

, Volume 73, Issue 2, pp 145–150 | Cite as

The Role of the Hemostatic System in Tumor Growth, Metastasis, and Angiogenesis: Tissue factor is a Bifunctional Molecule Capable of Inducing Both Fibrin Deposition and Angiogenesis in Cancer

Progress in hematology

Abstract

Cancer patients are prone to venous thromboembolism (VTE), and this hypercoagulability favors tumor growth and metastasis. After a brief review of the clinical aspects of VTE and cancer, we discuss the pathogenesis of hypercoagulability with an emphasis on the role of tissue factor (TF). The discovery that, in addition to tumor cells, TF is expressed by tumor-associated macrophages and tumor-associated endothelial cells led to studies of the role of TF in the regulation of tumor angiogenesis. In human lung cancer, melanoma, and breast cancer,TF and vascular endothelial growth factor (VEGF) co-localize in tumor cells; a close correlation exists between TF and VEGF synthesis (P = .001) in tumor cell lines and with angiogenesis in vivo in a severe, combined immunodeficient mouse model. Transfection of a TF/VEGF low-producing human tumor cell line with full length TF complementary DNA (cDNA) results in conversion to a high producer of TF and VEGF; transfection of a deletion-mutant TF cDNA lacking cytoplasmic serine residues restores full TF procoagulant activity but not VEGF synthesis to the cells. These results suggest that the cytoplasmic tail of TF is necessary for tumor cell VEGF synthesis. Targeting of TF in tumors and tumor-associated blood vessels is discussed as a strategy for drug delivery and rational anti-cancer and anti-angiogenesis drug design.

Key words

Hypercoagulability Angiogenesis Tissue factor Vascular endothelial growth factor 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Zhang Y, Deng Y, Luther T, et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice.J Clin Invest. 1994;94:1320–1327.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Abe K, Shoji M, Chen J, et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor.Proc Natl Acad Sci U S A. 1999;96:8663–8668.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Ott I, Fischer EG, Miyagi Y, Mueller BM, Ruf W. A role for tissue factor in cell adhesion and migration mediated by interaction with actin-binding protein 280.J Cell Biol. 1998;140:1241–1253.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Rickles FR, Levine M, Dvorak HB. Abnormalities of hemostasis in malignancy. In: Clowes A, George JN, Colman RW, Hirsh J, Marder VJ, eds.Hemostasis and Thrombosis. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2000;1131–1152.Google Scholar
  5. 5.
    Shoji M, Abe K, Nawroth PP, Rickles FR. Molecular mechanisms linking thrombosis and angiogenesis in cancer.Trends Cardiovasc Med. 1997;7:52–59.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Trousseau A. Phlegmasia alba dolens. In:Clinique Medicale de l’Hotel-Dieu de Paris. Paris, France: JB Balliere et Fils; 1865;3:654–712.Google Scholar
  7. 7.
    Rickles FR, Levine MN. Venous thromboembolism in malignancy and malignancy in venous thromboembolism.Haemostasis. 1998;28:43–49.PubMedGoogle Scholar
  8. 8.
    Rickles FR, Levine M, Edwards RL. Hemostatic alterations in cancer patients.Cancer Metastasis Rev. 1992;11:237–248.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Edwards RL, Rickles FR. Thrombosis and cancer. In: Pineo GF, Hull R, eds.Disorders of Thrombosis. Philadelphia, Pa: W.B. Saunders; 1996:374–382.Google Scholar
  10. 10.
    Levine MN, Rickles FR. Treatment of venous thromboembolism in cancer patients.Haemostasis. 1998;28:66–70.PubMedGoogle Scholar
  11. 11.
    Claggett GP, Anderson FA, Heit J, Levine MN, Wheeler HB. Prevention of venous thromboembolism.Chest. 1998;114 (suppl):531–560.CrossRefGoogle Scholar
  12. 12.
    Prandoni P. Antithrombotic strategies in patients with cancer.Thromb Haemost. 1997;78:141–144.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Virchow R.Gesammelte Abhaldungen zur Wissensdiafflichem Medicine. Frankfurt, Germany: Meidinger Sohn; 1856.Google Scholar
  14. 14.
    Edwards RL, Klaus M, Matthews E, McCullen C, Bona RD, Rickles FR. Heparin abolishes the chemotherapy-induced increase in plasma fibrinopeptide A levels.Am J Med. 1990;89:25–28.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in the cancer patient.Semin Thromb Hemost. 1999;25:173–182.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Shoji M, Hancock WW, Abe K, et al. Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and VEGF in human cancers.Am J Pathol. 1998;152:399–411.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Edwards RL, Rickles FR, Cronlund M. Abnormalities of blood coagulation in patients with cancer: mononuclear cell tissue factor generation.J Lab Clin Med. 1981;98:917–928.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Rickles FR, Edwards RL, Barb C, Cronlund M. Abnormalities of blood coagulation in patients with cancer: fibrinopeptide A generation and tumor growth.Cancer. 1983;51:301–307.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Contrino J, Hair GA, Kreutzer DL, Rickles FR. In situ detection of the expression of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease.Nat Med. 1996;2:209–215.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Qi J, Kreutzer DL. Fibrin activation of vascular endothelial cells: induction of IL-8 expression.J Immunol. 1995;155:867–876.PubMedGoogle Scholar
  21. 21.
    Contrino J, Goralnick S, Qi J, Hair G, Rickles FR, Kreutzer DL. Fibrin induction of tissue factor expression in human vascular endothelial cells.Circulation. 1997;96:605–613.PubMedGoogle Scholar
  22. 22.
    Bromberg ME, Konigsberg WH, Madison JF, Pawashe A. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation.Proc Natl Acad Sci U S A. 1995;92:8025–8029.Google Scholar
  23. 23.
    Zioncheck PF, Roy S, Vehar GA. The cytoplasmic domain of tissue factor is phosphorylated by a protein kinase C-dependent mechanism.J Biol Chem. 1992;267:3561–3564.PubMedGoogle Scholar
  24. 24.
    Rottingen JA, Enden T, Camerer E, Iversen JG, Prydz H. Binding of human factor VIIa to tissue factor induces cytosolic Ca2+ signals in J82 cells, transfected COS-1 cells, Madin-Darby canine kidney cells and in human endothelial cells induced to synthesize tissue factor.J Biol Chem. 1995;270:4650–4660.CrossRefPubMedGoogle Scholar
  25. 25.
    Zhang Y, Deng Y, Werndt T, et al. Intravenous somatic gene transfer with antisense tissue factor restores blood flow by reducing tumor necrosis factor-induced tissue factor expression and fibrin deposition in mouse meth A sarcoma.J Clin Invest. 1996;97:2213–2224.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature.Science. 1997;275:547–555.CrossRefPubMedGoogle Scholar
  27. 27.
    Hu Z, Sun Y, Garen A. Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model.Proc Natl Acad Sci U S A. 1999;96:8161–8166.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Contrino J, Hair GA, Schmeizl MA, Rickles FR, Kreutzer DL. In situ characterization of antigenic and functional tissue factor expression in human tumors utilizing monoclonal antibodies and recombinant factor VIIa as probes.Am J Pathol. 1994;145:1315–1322.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Dickinson CD, Kelly C, Ruf W. Identification of surface residues mediating tissue factor binding and catalytic function of the serine protease factor VIIa.Proc Natl Acad Sci U S A. 1996;93:14379–14384.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Sevinsky JR, Rao LVM, Ruf W. Ligand-induced protease receptor translocation into caveolae: a mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway.J Cell Biol. 1996;133:293–304.CrossRefPubMedGoogle Scholar
  31. 31.
    Iakhiaev A, Pendurthi UR, Voight J, Ezban M, Rao LVM. Metabolism of factor VIIa bound to tissue factor in fibroblasts in the presence and absence of tissue factor pathway inhibitor.J Biol Chem. 1999;52:36995–37003.CrossRefGoogle Scholar
  32. 32.
    Bierhaus A, Zhang Y, Quehenberger P, et al. The dietary pigment curcumin reduces endothelial tissue factor gene expression by inhibiting binding of AP-1 to the DNA and activation of NF-kappa B.Thromb Haemost. 1997;77:772–782.PubMedGoogle Scholar
  33. 33.
    Pendurthi UR, Williams JT, Rao LVM. Inhibition of tissue factor gene activation in cultured endothelial cells by curcumin: suppression of activation of transcription factors Egr-1, AP-1, and NF-κB.Arterioscler Thromb Vasc Biol. 1997;17:3406–3413.CrossRefPubMedGoogle Scholar
  34. 34.
    Arbiser JA, Klauber N, Rohan R, et al. Curcumin is an in vivo inhibitor of angiogenesis.Mol Med. 1998;4:376–383.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Adams BK, Davis MC, Ferstl EM, et al. Inhibition of tissue factor-mediated VEGF production and tumor cell growth by synthetic curcumin analogs [abstract].Blood.(suppl)1999;94:12a.Google Scholar

Copyright information

© The Japanese Society of Hematology 2001

Authors and Affiliations

  • Frederick R. Rickles
    • 1
  • Mamoru Shoji
    • 2
  • Keisuke Abe
    • 3
  1. 1.The George Washington University Medical CenterWashington
  2. 2.Emory University School of MedicineAtlanta
  3. 3.Hokkaido University School of MedicineSapporoJapan

Personalised recommendations